Physician profile
Dana F Mitchell
NPI 1659308450
$344,421.99
in general payments reported to CMS, 2019-2025
34 companies · $88K in 2025
The $88K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $12K · 2021: $37K · 2022: $78K · 2023: $62K · 2024: $53K · 2025: $88K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $95K · Consulting Fee: $50K · Travel and Lodging: $28K · Honoraria: $21K · Food and Beverage: $7,322 · Grant: $2,150 · Education: $32.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $95,209.00 |
| Consulting Fee | $49,700.87 |
| Travel and Lodging | $27,787.34 |
| Honoraria | $20,825.00 |
| Food and Beverage | $7,322.48 |
| Grant | $2,149.94 |
| Education | $32.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $106,655.40 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $78,470.97 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $51,981.19 | 2019-2025 | Krystexxa |
| Horizon Therapeutics Plc | $44,174.79 | 2019-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $40,152.47 | 2020-2025 | Acthar, Terlivaz |
| Mallinckrodt Enterprises LLC | $13,219.52 | 2019 | |
| Glaxosmithkline, LLC. | $6,439.87 | 2021-2025 | Benlysta |
| Akebia Therapeutics INC | $704.89 | 2020-2025 | Vafseo, Auryxia |
| Otsuka America Pharmaceutical, INC. | $354.99 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $319.04 | 2019-2023 | Veltassa |
| Opko Pharmaceuticals, LLC | $313.53 | 2019-2024 | Rayaldee |
| Calliditas Therapeutics US INC. | $225.77 | 2022-2025 | Tarpeyo |
| Abbott Laboratories | $200.24 | 2024-2025 | Armada, Esprit, Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.30 | 2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $127.32 | 2022-2024 | Lupkynis |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $121.12 | 2022-2024 | |
| Medtronic, INC. | $105.86 | 2021 | |
| Novartis Pharmaceuticals Corporation | $89.26 | 2023-2024 | |
| Fresenius USA Marketing, INC. | $81.91 | 2019-2021 | |
| Novo Nordisk INC | $69.33 | 2019-2024 | Rybelsus, Ozempic |
| Cordis US Corp. | $68.29 | 2023 | |
| Ardelyx, INC. | $56.17 | 2024 | Ibsrela |
| Ani Pharmaceuticals, INC. | $40.57 | 2025 | Purified Cortrophin Gel |
| Cormedix INC. | $37.72 | 2025 | Defencath |
| Genzyme Corporation | $37.10 | 2019-2021 | |
| Asahi Intecc USA, INC. | $35.71 | 2025 | Asahi Peripheral Vascular Wires |
| Pharmacosmos Therapeutics INC. | $28.13 | 2023 | Monoferric |
| Ultragenyx Pharmaceutical INC. | $28.05 | 2024 | Crysvita |
| Merck Sharp & Dohme LLC | $25.58 | 2025 | Prevymis |
| Apellis Pharmaceuticals, INC. | $23.38 | 2025 | Empaveli |
| Boston Scientific Corporation | $20.49 | 2020 | |
| Alnylam Pharmaceuticals INC. | $20.02 | 2021 | |
| Alexion Pharmaceuticals, INC. | $18.62 | 2022 | |
| Amicus Therapeutics, INC. | $17.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.